Drug Treatment of Sleep Disorders (Record no. 4782)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01771nam a22002897a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240305192324.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220210b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3319115146 |
| International Standard Book Number | 9783319115146 |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| Source | 2296-6056 |
| Source | 2296-6064 (electronic) |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | Data centre |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Antonio Guglietta |
| 9 (RLIN) | 30925 |
| 245 ## - TITLE STATEMENT | |
| Title | Drug Treatment of Sleep Disorders |
| Remainder of title | Milestones in Drug Therapy |
| 250 ## - EDITION STATEMENT | |
| Edition statement | illustrated |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Independent Pharmaceutical Consultant Barcelona Spain |
| Name of publisher, distributor, etc. | Springer |
| Date of publication, distribution, etc. | 2014 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 297 pages |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Science / Life Sciences / Neuroscience |
| 9 (RLIN) | 27050 |
| General subdivision | Medical / Psychiatry / Psychopharmacology |
| 9 (RLIN) | 30860 |
| General subdivision | Medical / Pharmacology |
| 9 (RLIN) | 27230 |
| General subdivision | Medical / Neuroscience |
| 9 (RLIN) | 26972 |
| General subdivision | Medical / Pharmacy |
| 9 (RLIN) | 27229 |
| General subdivision | Medical › Psychiatry › Psychopharmacology |
| 9 (RLIN) | 30926 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Shelving location | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 02/10/2022 | EBS9255 | 02/10/2022 | 02/10/2022 | E-BOOKS |